Corrigendum to "Combination of Cardiovascular, Kidney, and Metabolic Diseases in a Syndrome Named Cardiovascular-Kidney-Metabolic, With New Risk Prediction Equations" [<i>Kidney International Reports</i> Volume 9, Issue 9, September 2024, Pages 2608-2618].
對於「Combination of Cardiovascular, Kidney, and Metabolic Diseases in a Syndrome Named Cardiovascular-Kidney-Metabolic, With New Risk Prediction Equations」的更正 [<i>Kidney International Reports</i> 第9卷，第9期，2024年9月，頁2608-2618]。
Kidney Int Rep 2025-04-14
Corrigendum to "WCN24-1051 CLINICAL PROFILE, DIAGNOSIS, THERAPEUTIC INTERVENTION AND COMPLICATIONS IN RENAL BIOPSY IN CKD POPULATION - SINGLE CENTER 20 YEARS' EXPERIENCE" [<i>Kidney International Reports</i> Volume 9, Issue 4, Supplement, April 2024, Page S86].
對於「WCN24-1051 CLINICAL PROFILE, DIAGNOSIS, THERAPEUTIC INTERVENTION AND COMPLICATIONS IN RENAL BIOPSY IN CKD POPULATION - SINGLE CENTER 20 YEARS' EXPERIENCE」的更正 [<i>Kidney International Reports</i> 第9卷，第4期，補充，2024年4月，第S86頁]。
Kidney Int Rep 2024-07-31
Corrigendum to "The Association Between Metabolic Syndrome, Hyperfiltration, and Long-Term GFR Decline in the General Population" [<i>Kidney International Reports</i> Volume 8, Issue 9, September 2023, Pages 1831-1840].
對於「代謝症候群、高過濾率與一般人群長期GFR下降之間的關聯」的更正 [<i>Kidney International Reports</i> 第8卷，第9期，2023年9月，頁1831-1840]。
Kidney Int Rep 2024-07-31
Corrigendum to "WCN24-1267 EMPAGLIFLOZIN IMPROVES VITALITY AND PROTECT FROM ADVANCED GLYCATION END PRODUCTS IN ENDOTHELIAL CELLS" [<i>Kidney International Reports</i> Volume 9, Issue 4, Supplement, April 2024, Page S637].
對於「WCN24-1267 EMPAGLIFLOZIN 改善活力並保護內皮細胞免受高級糖化終產物的影響」的更正 [<i>Kidney International Reports</i> 第9卷，第4期，補充，2024年4月，第S637頁]。
Kidney Int Rep 2024-07-31
Corrigendum to "Nitric Oxide Precursors and Dimethylarginines as Risk Markers for Accelerated Measured GFR Decline in the General Population" [<i>Kidney International Reports</i> Volume 8, Issue 4, April 2023, Pages 818-826].
對於「Nitric Oxide Precursors and Dimethylarginines as Risk Markers for Accelerated Measured GFR Decline in the General Population」的更正 [<i>Kidney International Reports</i> 第8卷，第4期，2023年4月，頁818-826]。
Kidney Int Rep 2024-07-31
Corrigendum to "WCN24-658 Comparative Analysis of Zwitterionic Materials and Polyvinyl Pyrrolidone for Enhancing Dialysis Membrane Hemocompatibility and Psychological Symptoms in Patients" [<i>Kidney International Reports</i> Volume 9, Issue 4, Supplement, April 2024, Pages S362-S363].
對於「WCN24-658 比較分析 Zwitterionic 材料和聚乙烯吡咯烷酮以增強透析膜的血液相容性及患者的心理症狀」的更正 [<i>Kidney International Reports</i> 第9卷，第4期，補充，2024年4月，頁S362-S363]。
Kidney Int Rep 2024-08-19
看起來你提到的是一篇有特定 DOI 的文章的更正。如果你需要幫助理解這個更正、總結文章內容，或是有其他相關的問題，請提供更多細節！
PubMedDOI
Corrigendum to "WCN24-465 RISK OF MORTALITY IN PATIENTS RECEIVING HIGH-VOLUME ONLINE HEMODIAFILTRATION (OL-HDF) VERSUS HIGH-FLOW HEMODIALYSIS (HD) THERAPY IN 14 FRESENIUS MEDICAL CARE ECUADOR (FMC) CLINICS" [<i>Kidney International Reports</i> Volume 9, Issue 4, Supplement, April 2024, Page S359].
對於「WCN24-465 高容量線上血液透析 (OL-HDF) 與高流量血液透析 (HD) 治療在 14 家 Fresenius Medical Care Ecuador (FMC) 診所中患者死亡風險的比較」的更正 [<i>Kidney International Reports</i> 第 9 卷，第 4 期，補充，2024 年 4 月，第 S359 頁]。
Kidney Int Rep 2024-08-19
看起來你提到的是一篇有特定 DOI 的文章的更正。如果你需要幫助理解這個更正、總結文章內容，或是其他相關資訊，請提供更多細節！
PubMedDOI
Corrigendum to "WCN24-1709 NON-CADAVERIC HOMOLOGOUS VEIN AS VASCULAR ACCESS IN A PATIENT WITH EXHAUSTED NATIVE VEINS ON HEMODIALYSIS" [<i>Kidney International Reports</i> Volume 9, Issue 4, Supplement, April 2024, Pages S398-S399].
對於「WCN24-1709 非屍體同源靜脈作為一名在透析中原生靜脈耗竭患者的血管通路」的更正 [<i>Kidney International Reports</i> 第9卷，第4期，補充，2024年4月，頁S398-S399]。
Kidney Int Rep 2024-08-19
Corrigendum to "Renal Disease in Metabolic Syndrome: the Hidden Role of Intrarenal Ischemia" [<i>Kidney International Reports</i> Volume 9, Issue 5, May 2024, Pages 1419-1428].
對於「Renal Disease in Metabolic Syndrome: the Hidden Role of Intrarenal Ischemia」的更正 [<i>Kidney International Reports</i> 第9卷，第5期，2024年5月，頁1419-1428]。
Kidney Int Rep 2025-02-24
Corrigendum to "Avoid Preanalytical Errors When Using Urine Biomarkers of Exposure" [<i>Kidney International Reports</i> Volume 10, Issue 1, January 2025, Page 281].
對於「避免在使用尿液暴露生物標記時產生前分析錯誤」的更正 [<i>Kidney International Reports</i> 第10卷，第1期，2025年1月，第281頁]。
Kidney Int Rep 2025-04-14